Oncology 101: A Hematology and Oncology Primer for Advanced Practice Providers - Enduring

Oncology 101: A Hematology and Oncology Primer for Advanced Practice Providers - Enduring

The demand for cancer care is expected to grow 40% over the next six years and ASCO is projecting a shortage of more than 2,200 oncologists by 2025. To meet the cancer care needs of patients, advanced practice providers (APPs), whose education and training is focused on health promotion, disease prevention, and primary care medical management, have increasingly been sought to fill the shortage. However, many APPs have little background or training in oncology. As a result, oncology practices need to provide new staff with an onboarding program that helps to establish a working baseline level of knowledge of hematology and oncology.

To help APPs prepare for a new career in the specialty of oncology, Horizon CME in partnership with APAO has developed “Oncology 101: A Hematology and Oncology Primer for Advanced Practice Providers”. In this activity, clinicians will gain a basic understanding of cancer therapies, benign and malignant hematologic disorders, solid malignancies, supportive care strategies, genetics, molecular testing, and more. Participation in this activity will help pave the way for APPs to provide support and care to cancer patients as part of the multidisciplinary oncology care team. 

 

Target Audience

Oncology 101 is developed with and for advanced practice providers including PA, NP, PharmD and RN.

As part of the multidisciplinary team in the care of cancer patients, students, physicians, and other healthcare professionals involved in the management of cancer patients are also welcome to attend.

 

Learning Objectives

Upon completion of this activity, participants should be better able to: 

  1. Describe the presentation, evaluation, and treatment of common solid and hematologic malignancies
  2. Recognize the presentation, evaluation, and treatment of common benign hematologic disorders 
  3. Summarize the role of genetics and molecular testing in cancer care 
  4. Compare and contrast the various types of cancer treatment including stem cell transplant, chemotherapy, targeted therapies, radiotherapy, and immunotherapy
  5. Identify and appropriately manage common oncologic emergencies
  6. Outline the role of palliative care and effectively incorporate it into oncology practice

 

Activity Start Date -   April 12th, 2022

Expiration Date -  April 12th, 2023

Course summary
Available credit: 
  • 10.00 AMA PRA Category 1 Credit
    Horizon CME designates this Enduring activity for a maximum of 10.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 10.00 ANCC
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. This course is approved by the Nurse Practitioner Healthcare Foundation, California Board of Registered Nursing, CEP# 16441. Upon completion, NPs and RNs will be awarded up to 10.00 credit.
  • 5.25 Pharmacology
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. This course is approved by the Nurse Practitioner Healthcare Foundation, California Board of Registered Nursing, CEP# 16441. Upon completion, NPs and RNs will be awarded up to 5.25 credit.
Course opens: 
04/12/2022
Course expires: 
04/12/2023
Cost:
$75.00
Rating: 
0

(01) Introduction to Malignant Hematology (1.75 CE)

Objectives

  • Define the clinical manifestations, diagnostic modalities, and basic treatment strategies for the common hematologic malignancies (ALL, AML, MDS, MF, CLL, CML, HL, NHL, MM, and MGUS).

  • Describe the sub-types of non-Hodgkin lymphoma, including defining characteristics.

  • Summarize the impact of molecular and genetic testing in hematologic malignancies.


» Jennie M. Goble, PA-C – Mayo Clinic (35 minutes) - Acute lymphocytic leukemia (ALL), Acute myelogenous leukemia (AML), Myelodysplastic syndromes, and Myelofibrosis. 

» Amy Goodrich, RN, MSN, CRNP – Johns Hopkins (20 minutes) - Chronic lymphocytic leukemia (CLL) and Chronic myelogenous leukemia (CML).

» Bruce Christensen, PA-C – UT Health San Antonio (20 minutes) - Hodgkin lymphoma and Non-hodgkin lymphoma.

» Beth Faiman, PhD, CNP – Cleveland Clinic (30 minutes) - Multiple myeloma, Monoclonal gammopathy of undetermined significance (MGUS), and Amyloidosis and Waldenstroms.


(02) Introduction to Benign Hematology (1.25 CE)

Objectives

  • Review the diagnosis and management of common red cell, white cell, and platelet disorders. 

  • Describe strategies for prophylaxis and management of coagulopathies. 

  • Outline updated treatment for benign hematologic conditions.


» Beth Faiman, PhD, CNP – Cleveland Clinic (35 minutes) - Anemia, Idiopathic and Immune TP (ITP), and Essential thrombocytosis.

» Lauren Imboden, PA-C – Atrium Health Wake Forest Baptist (40 minutes) - Polycythemia, Hemophilia, and Coagulopathies (factor V leiden, VTE).


(03) Introduction to Solid Malignancies (1.50 CE)

Objectives

  • Define the clinical manifestations, diagnostic modalities, and basic treatment strategies for the common solid malignancies (breast CA, lung cancer, colorectal cancer, prostate cancer, and bladder cancer).

  • Describe the risk factors and molecular basis for solid tumors.

  • Summarize the role of molecular and genetic testing in management of solid malignancies.


» Kristi Kay Orbaugh, NP – Community Hospital Oncology Physicians (25 minutes) - Breast Cancer.

» Beth Sandy, MSN, CRNP – Penn Medicine (25 minutes) - Lung Cancer.

» Kathleen Boyle, PA-C – Dana Farber (15 minutes) - Colorectal cancer.

» Victoria Wong, PA-C – Fox Chase Cancer Center (25 minutes) - Prostate and bladder cancer.


(04) Chemotherapy Review (0.75 CE)

Objectives

  • Describe the rationale of combination chemotherapy.

  • List the major chemotherapy drug classifications and their mechanism of action.

  • Identify the major toxicities associated with chemotherapy.

» Sandra Cuellar, PharmD, BCOP – University of Illinois Chicago.


(05) Targeted Therapies (0.50 CE)

Objectives

  • Review the mechanism of action for targeted therapies.

  • Outline the indications for currently available targeted therapies.

  • Recognize common side-effects associated with targeted therapies.

» Jennifer Murphy, PharmD, BCOP – UC Davis.


(06) Basics of Radiation Oncology (0.50 CE)

Objectives

  • Review the role and history of radiation therapy (RT).

  • Discuss the physical and biological basis for RT.

  • Outline the clinical applications of RT in the management of cancer.

  • Describe the RT process including simulation, treatment planning, and delivery.

  • Identify the types of RT available.

» Maitry Patel, PA-C – University Health Network, Toronto.


(07) Immunotherapies (0.50 CE)

Objectives

  • Review the mechanism of action for targeted therapies.

  • Outline the indications for currently available targeted therapies.

  • Recognize common side-effects associated with targeted therapies.

» Joslyn Rudoni, PharmD, BCOP – Cleveland Clinic Taussig Cancer Center.


(08) Supportive Care (1.00 CE)

Objectives

  • Describe standard preventive medications for acute and delayed emesis based on the emetic risk of the anticancer regimen.

  • Develop a diagnostic approach to differentiate iron deficiency anemia, anemia of inflammation, cancer-related anemia and cancer treatment-related anemia.

  • Identify febrile neutropenia and implement evidence-based management strategies.

  • Discuss prevention and treatment of oral and gastrointestinal mucosal injury.

  • Identify strategies for the management of infusion reactions to systemic anticancer therapy.

» Laura J. Zitella, MS, RN, ACNP-BC, AOCN – UCSF.


(09) CAR-T Cell Therapy (0.50 CE)

Objectives

  • Describe the mechanisms of action and clinical indications for CAR T-cell therapy.

  • Apply strategies to appropriately assess and manage the potential acute and long-term toxicities associated with CAR T-cell therapy.

» Sherry Adkins, RN, MSN, ANP-C – MD Anderson.


(10) Oncologic Emergencies (0.75 CE)

Objectives

  • Explain the risk factors and interventions for febrile neutropenia and sepsis and apply them to patient management.

  • Describe the pathophysiology for tumor lysis syndrome and list the risk factors and appropriate interventions.

  • Recognize and provide appropriate interventions for infusion reactions, hypersensitivity reactions, and cytokine release syndrome.

  • State the common oncology emergencies for immunotherapy and identify them in patients.

  • List the signs, symptoms, and interventions for immune induced pneumonitis, endocrinopathies, and colitis.

» Brenda Shelton, DNP, APRN-CNS, RN, CCRN, AOCN – Johns Hopkins.


(11) Stem Cell Transplant (0.50 CE)

Objectives

  • Identify the types of stem cell transplant and the conditions in which it is used to treat.

  • List conditioning regimens used for stem cell transplant.

  • Describe the pathophysiology, presenting symptoms and treatment of acute and chronic GVHD.

» Linda M. Perry, PA-C – Penn Medicine.


(12) Palliative Care (0.50 CE)

Objectives

  • Define palliative care and hospice.

  • Identify strategies for integrating palliative care into oncology practices.

» Sarah Lowry, DNP, ACNP-BC, AOCNP, ACHPN – OHSU.

 

Planning Committee

Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN

Nurse Practitioner

Department of Hematology and Medical Oncology 

Cleveland Clinic 

Cleveland, OH

Bio
Dr. Beth Faiman received a bachelor of science in nursing and registered

nurse certification at Ursuline College in Pepper Pike, Ohio, completed in 1996.

She received a master of science in nursing and certification as an adult nurse

practitioner at Kent State University in Kent, Ohio in 2002 and a PhD in Clinical Research

and Nursing from Case Western Reserve University in 2014. Dr. Faiman holds

an advanced oncology nurse certification through ONCC. She is currently employed

as an Adult Nurse Practitioner in the department of Hematologic Oncology and

Blood Disorders at the Cleveland Clinic in Cleveland, Ohio.

 

She is adjunct faculty at Ursuline College, Case Western Reserve University and

Kent State University. She received the 2012 Excellence in Medical Oncology and

2013 Commendation for Patient and Nursing Education Award sponsored by

The Oncology Nursing Society and the 2015 Dean’s Legacy Award for PhD Studies from

Case Western Reserve University and was named the Leukemia and Lymphoma

Society’s Woman of the Year for Cleveland and Akron Ohio, 2016. Faiman was inducted

as a Fellow in the American Academy of Nursing (FAAN) in 2019.

 

Val R. Adams, PharmD, FCCP, FHOPA, BCOP

Associate Professor, Oncology Specialist

University of Kentucky

Lexington, KY

 

Bio 

Val Adams has worked in Oncology and Immunology since starting

Hematology/Oncology residency training in 1993. As a faculty member,

he has didactic teaching as well as experiential education. Val has served as the

oncology residency director for over 20 years and has trained 40 oncology residents.

He currently co-chairs the PRMC for the NCI Cancer Center grant, which funds part

of his salary.

 

Beth Sandy, MSN, CRNP

Nurse Practitioner, Thoracic Medical Oncology

Abramson Cancer Center, University of Pennsylvania

Philadelphia, PA

Bio 

Beth Sandy is a nurse practitioner at the Abramson Cancer Center at the

University of Pennsylvania. She specialized in thoracic malignancies and has

been in this thoracic oncology NP position for 17 years, and an oncology nurse

for 22 years. She serves on various editorial boards and has published in

several peer-reviewed medical journals. She speaks nationally and internationally

on the topics of lung cancer and the supportive care needs of lung cancer patients.

 

 

Colleen Tetzlaff, MHS, PA-C
Physician Assistant
Fox Chase Cancer Center
Philadelphia, PA

Bio

It has been a privilege to care for cancer patients and their families

as a Physician Assistant at Fox Chase Cancer Center since 2009.  As a Physician

Assistant, I collaborate with Attending Physicians to provide compassionate,

evidence-based care to patients with prostate, kidney, bladder, penile, adrenal

and testicular cancers.

 

My passion for oncology began when I was a nurse and cared for postoperative

cancer patients on an inpatient surgical floor, followed by nursing in an outpatient surgical

oncology clinic.  I entered the Duke University Physician Assistant Program knowing that

I wanted to make a difference in the lives of cancer patients and become a part of the

dynamic and fast-growing oncology field.

At Fox Chase Cancer Center, we are fortunate to work with outstanding
researchers that

enable us to offer patients novel therapies on clinical trials. Actively being a part of the trials 

that are changing how we treat cancer is exciting and invigorating.   I strive to support not

only the patient, but their entire family and support network, throughout all phases of their

cancer. I am honored to be a part of the genitourinary medical oncology team and privileged

to care for such inspiring patients and families every day.

 

Speakers

Jennie M. Goble, PA-C

Instructor in Medicine

Mayo Clinic

Rochester, MN

 

Bio

Jennie Goble is a Physician Assistant in the Division of Hematology at the Mayo Clinic

in Rochester, MN. She is an Instructor in the College of Medicine and has a Master’s

degree in Physician Assistant Studies. Jennie has been a Physician Assistant in

Hematology for almost 9 years and has practiced in both the inpatient and hospital

outpatient settings. She is Silver Quality certified and frequently participates in projects

and in education and mentoring of new providers. Clinical interests include acute leukemia

and high-grade lymphoma Her passions are high-quality patient care, NPPA education, and

quality improvement.

 

Amy Goodrich, NP-AC

Research Associate

Johns Hopkins University

Nurse Practitioner

The Johns Hopkins Kimmel Cancer Center

Baltimore, MD

 

Bio

Amy Goodrich, RN, MSN, CRNP, Research Associate, is a Nurse Practitioner in the

Hematologic Malignancies Program and Research Nursing Manager at The Johns

Hopkins Kimmel Cancer Center in Baltimore, Maryland. Ms. Goodrich manages patients

with various types of hematologic malignancies, concentrating on lymphomas. She also

manages the Cancer Center’s research nurses and is extremely involved in research

operations.

 

Bruce Christensen, PA-C
Physician Assistant
UT Health San Antonio
San Antonio, TX

 

Bio

Bruce Christensen is an assistant professor is in the Division of Hematology and

Oncology at the University of Texas Health Science Center San Antonio. He received

his initial training in the United States Air Force University of Nebraska Medical Center

physician assistant program. He later received his Master of Physician Assistant Studies

degree with an emphasis in oncology and a doctorate in health science with an emphasis

in leadership and organizational behavior. He retired from the USAF with rank of major in 2007.

 

He has served on the board of directors of the Texas Academy of Physician Assistants and

currently serves on the board of directors for the Association of Physician Assistants in Oncology.

He is a Distinguished Fellow of the American Academy of Physician Assistants. He joined Mays

Cancer Center, home to UT Health San Antonio MD Anderson, in April 2013, specializing in

malignant hematology.

 

Lauren Imboden, MMS, PA-C

Physician Assistant
Atrium Health Wake Forest Baptist
Winston Salem, NC

 

Bio

Lauren Imboden MMS, PA-C is a physician associate in the Department of Internal

Medicine, Section of Hematology and Oncology at Atrium Wake Forest Baptist

Health. Graduating from Wake Forest Medical School Physician Assistant program

in 2010. She joined the Hematology & Oncology Section in 2010 focusing on chronic

malignant hematologic disorders. In 2016 she transitioned to adult non-malignant

hematology where she splits her clinical time between the Comprehensive Cancer

Center caring for general hematology disorder patients and the Hemophilia

Treatment Center caring for patients with bleeding and clotting disorders. She is

a native North Carolinian, born in the Foothills of NC and residing since 2006 in

Winston-Salem, NC with her spouse and 2 children.

 

Kristi Kay Orbaugh, MSN, RN, NP, AOCN

Adult Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, IN

 

Bio

Kristi Kay Orbaugh, RN, MSN, RNP, AOCN, is an Adult Nurse Practitioner for Community

Hospital Oncology Physicians in Indianapolis, IN. She received her master’s degree in

nursing from the Indiana University-Purdue University of Indianapolis and is certified as a nurse practitioner and advanced oncology nurse. Ms Orbaugh previously held adult nurse

practitioner positions with Quality Oncology and Indiana Oncology Hematology Consultants.

She is a frequent speaker on a variety of oncology-related subjects and has presented on the

local, regional, national, and international levels. She is a member of the American Academy of

Nurse Practitioners (AANP) and the Oncology Nursing Society (ONS).

 

Victoria Wong, PA-C
Physician Assistant, Department of Hematology/Oncology
Fox Chase Cancer Center
Philadelphia, PA

 

Bio

Victoria Wong is a physician assistant in the division of genitourinary malignancies

at Fox Chase Cancer Center in Philadelphia, focusing on prostate, kidney, bladder,

testicular, adrenal, and penile cancers. Victoria received her undergraduate Bachelor

of Science degree in biology with a concentration in developmental genetics at Stony

Brook University. She received her master of medical science degree from Salus

University in 2016. Victoria also serves as social media co-chair for Association of PAs in

Oncology (APAO).

 

Kathleen Boyle, PA-C

Physician Assistant

Dana-Farber Cancer Institute

Boston, MA

 

Bio

Kathleen Boyle is a physician assistant (PA) at Dana-Farber Cancer Institute’s (DFCI)

Gastrointestinal Cancer Center based in Boston, Massachusetts. Ms. Boyle holds a

Bachelor of Science in biology and a Bachelor of Science in environmental studies

from Fordham University. She holds a Master of Science in medical studies from Yale

University School of Medicine. She is currently enrolled at Massachusetts College of

Pharmacy and Health Sciences University as a candidate for a Doctor of Science in

Physician Assistant Studies.

 

 

Sandra Cuellar Puri, PharmD, BCOP

Clinical Oncology Pharmacist

University of Illinois College of Pharmacy

Chicago, IL

 

Bio

Sandra Cuellar, Pharm.D., BCOP, is a Clinical Associate Professor in the Department of

Pharmacy Practice at the University of Illinois at Chicago (UIC) College of Pharmacy.

Dr. Cuellar has been active in the field of hematology/oncology for 17 years. She is

the coordinator and clinical associate professor for oncology therapeutics.

Dr. Cuellar received her Bachelor of Liberal Arts from Augustana College in Rock

Island, Illinois, followed by her Pharm.D. degree from the University of Illinois at

Chicago College of Pharmacy. She then completed a Pharmacy Practice Residency

at University of Kentucky Chandler Medical Center. Following her residency, she

completed a specialty oncology residency at MD Anderson Cancer Center in Houston,

Texas. She currently is the clinical pharmacist in the Out-Patient Cancer Center,

director of the oncology specialty residency program, and vice-chair of IRB at UIC.

Dr. Cuellar is an editor at large for Journal of Hematology Oncology Pharmacy and

is involved in research, consulting and publications in the field of hematology/

oncology. She has given multiple national and international presentations on cardio oncology,

supportive care, and oncology therapeutics. In addition, Dr. Cuellar serves as an ASHP oncology

surveyor and continues to serve on multiple committees for

Hematology Oncology Pharmacy Association.

 

 

Jennifer Murphy, PharmD, BCOP, BCPS
Senior Pharmacist
UCD Health, Oncology & Investigational Drug Service
San Francisco, CA

 

Bio

Jennifer Murphy graduated from the UC San Francisco School of Pharmacy where

she received her Doctor of Pharmacy degree where she won the ASHP National

Clinical Skills Competition and SNPh A National Clinical Skills Competition. After

graduation, she completed an Acute Care PGY1 Residency at UC San Diego Health

System and a PGY2 Residency in Oncology at UC Davis Health.

As a Board Certified Oncology Pharmacist, her primary area of practice is the UCDH

Cancer Center Investigational Drug Service. In this role, she is actively involved in

oncology clinical trial protocol development and quality improvement projects as

well as various institutional committees. Additionally, she supports the Inpatient

Hematology/Oncology, Bone Marrow Transplant and Gynecologic Oncology services.

Dr. Murphy developed the Pharmacy Residency Mentorship Committee in 2014 and

co-chairs the Committee. Dr. Murphy has served as an adjunct faculty and guest

lecturer at California Northstate University, College of Pharmacy and currently

holds a volunteer faculty position as an assistant professor at UCSF School of

Pharmacy.

 

Maitry Patel, CCPA
Canadian Certified Physician Assistant
Radiation Oncology
University Health Network, Toronto

 

Bio

Maitry Patel is a Radiation Oncology Physician Assistant at UHN, working in multiple

disease sites within oncology clinics since her graduation from the McMaster

Physician Assistant Education Program in 2014, while being actively involved in the

PA community. She is an Instructor within the Department of Family Medicine at

McMaster University. Since 2019, she has served as the Alternate Director of the

Ontario Chapter on the CAPA Board of Directors. She is active in multiple capacities

within the Association of PAs in Oncology.

 

Maitry has been the recipient of CAPA honor roll for her work in progressing the PA

profession nationally, Excellence in Patient Experience, and Excellence in teaching

support awards. She has a special interest in developing easily accessible patient

education material and advocating for equal delivery of care across the board. Maitry

is now pursuing an Global Executive MBA at the Rotman School of Management at the

University of Toronto with a focus on Healthcare and the Life Sciences.

 

Joslyn Rudoni, PharmD, BCOP
Hematology/Oncology Clinical Pharmacist
Cleveland Clinic Taussig Cancer Center
Cleveland, OH

 

Bio

Joslyn Rudoni, PharmD, BCOP, is a Clinical Pharmacy Specialist in Hematology/

Oncology and the Lymphoma/Myeloma Pharmacy Team Lead at the Cleveland Clinic

Taussig Cancer Institute. She serves as a preceptor for residents of the Cleveland

Clinic Pharmacy Residency Program and for students from over ten different

pharmacy schools across the country. Additionally, Dr. Rudoni is an Assistant

Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case

Western Reserve University. Dr. Rudoni graduated from the University of Michigan

College of Literature, Science, and the Arts with her Bachelor of Science degree in

Cellular and Molecular Biology with a minor in German Studies. Afterwards, she

went on to earn her Doctor of Pharmacy degree from the University of Michigan

College of Pharmacy and complete her PGY-1 Pharmacy Residency at Michigan

Medicine and her PGY-2 Oncology Pharmacy Residency at The University of Texas

MD Anderson Cancer Center.

 

Laura J. Zitella, MS, RN, ACNP-BC, AOCN
Associate Clinical Professor
University Of California San Francisco
Hematology/Oncology Nurse Practitioner
San Francisco, CA

 

Bio

Laura Zitella, MS, RN, ACNP-BC, AOCN has twenty years of experience caring for

patients with malignancies including undergoing stem cell transplant. She has

presented hundreds of educational presentations, co-edited a hematology textbook,

authored several chapters in oncology texts, published peer-reviewed journal articles,

and planned multiple educational events.

 

 

Sherry Adkins, RN, MSN, ANP-C
Advanced Practice Provider Supervisor for Lymphoma Research
The University of Texas MD Anderson Cancer Center
Houston, Texas

 

Bio

Sherry Adkins, RN, MSN, ANP-C has been an Advanced Practice Nurse for more than

20 years. After completing an Advanced Practice Oncology Fellowship Program at the

University of Texas Health Science Center 10 years ago, she began working as a nurse

practitioner in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center

in Houston. Over the past two years, she have worked in Lymphoma Research with Dr.

Sattva Neelapu in leading multiple CAR T-cell therapy clinical trials including the ZUMA-1

Registry Trial which led to the release of the first commercial CAR T-cell therapy for the treatment

of Lymphoma. She also played a major role in developing their commercial CAR T-cell Program.

 

Brenda Shelton. DNP, APRN-CNS, CCRN, AOCN

Instructor

The Johns Hopkins University School of Nursing, Clinical

Nurse Specialist, Sidney Kimmel

Comprehensive Cancer Center at

Johns Hopkins, Baltimore, MD

 

Bio

Ms Shelton has over 43 years of experience in critical care nursing, with a primary

focus of oncology critical care for more than three decades. She has presented

regionally and nationally on the topics of sepsis/ infection, cardiac disease/ toxicities,

pulmonary disease/ toxicities in oncology and received a doctorate of nursing practice

(DNP) with a capstone project of implementing the sepsis guidelines in a

hematology[1]oncology unit. Ms Shelton is an active leader in the Acute and Critical Care

Special Interest Group of the Oncology Nursing Society, Chairs the organization’s Task Force

for Evidence-based Management of Dyspnea, and also works as an Intermittent

Joint Commission International Nurse Surveyor. She has received awards from the

Oncology Nursing Society for Nurse Mentorship (2002), and the Excellence in Clinical

Publication Award (2017) and the Johns Hopkins Hospital Shirley Sohmer Nursing

Research Award in 2017. Ms Shelton has published more than 100 journal articles or

book chapters, and co-authored three texts.

 

Linda M. Perry, PA-C
Physician Assistant
Hematology
Perelman Center for Advanced Medicine
Philadelphia, PA

 

Bio

Linda Perry is a physician assistant at the Abramson Cancer Center at the University

of Pennsylvania. She specialized and has been practicing in stem cell transplant

for the past 19 years. She practices in the Allogeneic Stem Cell Transplant Program

at the University of Pennsylvania. She is a member of American Society for

Transplantation and Cellular Therapy and is an Editorial Board Member of HEMONC

TODAY.

 

Sarah Lowry, DNP, ACNP-BC, AOCNP, ACHPN
Assistant Professor of Medicine
Division of Hematology/Medical Oncology, School of Medicine
Beaverton, OR

 

Bio

Sarah became an oncology nurse in 2005 and has found the most fulfillment in

supporting quality of life and well-being for patients and families going through cancer

treatment. She became an oncology nurse practitioner and moved to Oregon in 2013

to work with OHSU’s Community Hematology and Oncology group, and has been a

palliative care provider for the group since 2014. She enjoys working collaboratively

with the oncology teams to help patients live as well as possible through their cancer

journeys. She obtained her national certification in palliative care and earned her

doctorate degree in 2017 with a focus on improving outpatient advance care planning.

Outside of work, she enjoys gardening, food preservation, and anything that involves

being outside. She and her family were sucked into the pandemic chicken trend last

summer, and are the proud keepers of four lovely ladies.

 

FINANCIAL DISCLOSURES & CONFLICTS OF INTEREST

Horizon CME requires all planners, faculty, and other contributors to disclose any financial relationships with an ACCME defined ineligible company within the past 24 months and Horizon CME has resolved any conflicts prior to this educational activity.

Faculty

Amy Goodrich has served on Advisory Boards for AbbVie, AstraZeneca, BeiGene, Fresnius Kabi, and Sanofi.

Lauren Imboden has served on a Speakers Bureau for Dova Pharmaceutical and on Advisory Boards for Dova Pharmaceutical, Sanofi Genzyme and Genentech.

Kristi Kay Orbaugh has served on Speakers Bureau’s for BristolMeyerSquibb, AstraZeneca, DSI, Morphosys, Gilead, Lilly, Coherus, Dova.

Victoria Wong has served on an Advisory Board for Foundation Medicine.

Sandra Cuellar has served on an Advisory Board for Genentech & Seagen. Sandra Cuellar has served on Speaker Bureau for Genentech & Seagen.

Dr. Jennifer Murphy has stock holdings in Abbott, AbbVie, Moderna, Pfizer, iShares Biotechnology ETF, Laboratory Corporation of America Holdings.

Joslyn Rudoni discloses serving on a Speakers Bureau for Sanofi. Additionally, she discloses having served on Advisory Boards with Abbvie, BTG Medical, GlaxoSmithKline, Seagen, Jannsen, and AstraZeneca as well as having served as a consultant with CBPartners/Exeter Pharma Consultancy, and HMP Global during the past 24 months but those financial relationships have now ended.

Linda M. Perry`has served on a Speakers Bureau for Incyte and Abbvie, an Advisory Board for Incyte and Kadmon, and as a consultant for Kadmon and Incyte.

All other faculty disclosed no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

Planning Committee

Beth Sandy has served on Speakers Bureaus for Merck, Takeda, Amgen, Jazz and AstraZeneca. Megan Price has served on a speakers bureau for Ipsen Pharmaceuticals, Taiho Oncology, and Coherus Pharmaceuticals.

Val Adams has served as a Research Investigator for Bristol Myers Squibb.

All other planning committee members disclosed no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

Other Contributors

All non-faculty contributors and others involved in the planning, development, and editing/review of the content disclosed no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

Disclaimer

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Disclosure of Unlabeled Use

Horizon CME requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

Copyright Information

Copyright© 2021 by Horizon CME. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from Horizon CME.

Available Credit

  • 10.00 AMA PRA Category 1 Credit
    Horizon CME designates this Enduring activity for a maximum of 10.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 10.00 ANCC
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. This course is approved by the Nurse Practitioner Healthcare Foundation, California Board of Registered Nursing, CEP# 16441. Upon completion, NPs and RNs will be awarded up to 10.00 credit.
  • 5.25 Pharmacology
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. This course is approved by the Nurse Practitioner Healthcare Foundation, California Board of Registered Nursing, CEP# 16441. Upon completion, NPs and RNs will be awarded up to 5.25 credit.

Price

Cost:
$75.00
Please login or register to take this course.

Required Hardware/software

Access to the internet is required.

Supported Browsers:

Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above

Google Chrome 28.0+ for Windows, Mac OS, or Linux

Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux

Safari 6.0+ for Mac OSX 10.7 and above

 

Supported Phones & Tablets:

 Android 4.0.3 and above

iPhone/iPad with iOS 6.1 or above